On 27 June 2018, orphan designation (EU/3/18/2038) was granted by the European Commission to PPD Global Ltd, United Kingdom, for palovarotene for the treatment of multiple osteochondromas.
The sponsorship was transferred to PPD Bulgaria EOOD, Bulgaria, in April 2019 and subsequently to Ipsen Pharma, France, in May 2021.
Treatment of multiple osteochondromas
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.